Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Dynamic monitoring of circulating plasma cells in multiple myeloma: A Prospective multicenter study in China

Qun Li, Xiaojing Yan, Jian-Qing Mi, Aijun Liao, Bingzong Li, Hui-Han Wang, Huili Cai, Yafei Wang, Li Cai, Yu Hu, Chunyan Sun

Blood (2025) 146 (Supplement 1): 3984.

https://doi.org/10.1182/blood-2025-3984

Published: 2025

Journal Articles

Simvastatin targets the cholesterol–bile acid axis to improve ALL survival by remodeling the metabolic microenvironment

Junyu Wang, Bo Jiao, Tuantuan Gui, Xuan Liu, Shan-Shan Guo, Cheng Wang, Weiyang Liu, Li-Jun Peng, Jiayi Ren, Ming Zhang, Yun Tan, Duohui Jing, Jian-Qing Mi, Tong Yin, Hai Fang, Sai-Juan Chen, JIN WANG

Blood (2025) 146 (Supplement 1): 3362.

https://doi.org/10.1182/blood-2025-3362

Published: 2025

Journal Articles

Long-term follow-up for newly diagnosed BCR::ABL1 negative B cell acute lymphoblastic leukemia from China: 10-year outcome of RJ-ALL 2014 protocol

Jiayi Ren, Li-Jun Peng, Weiyang Liu, Jiong Hu, Cheng Wang, Yuchen Yan, Yuanfang LIU, Weiping Zhang, JIN WANG, Jian-Qing Mi

Blood (2025) 146 (Supplement 1): 3333.

https://doi.org/10.1182/blood-2025-3333

Published: 2025

Journal Articles

Long-read profiling of structural variants reveals mechanisms of chemo-resistance and prognostic heterogeneity in acute lymphoblastic leukemia

Xiaofang Ma, Minghao Jiang, JIN WANG, Jian-Qing Mi, Jason W.H. Wong, Duohui Jing

Blood (2025) 146 (Supplement 1): 1585.

https://doi.org/10.1182/blood-2025-1585

Published: 2025

Journal Articles

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Blood (2025) 146 (Supplement 1): 3889.

https://doi.org/10.1182/blood-2025-3889

Published: 2025

Journal Articles

Association of combined IKZF1plus genotype and ABL1 mutations with outcomes in adult BCR::ABL1-positive acute lymphoblastic leukemia

Cheng Wang, Jianfeng Li, Weiyang Liu, Yuchen Yan, Li-Jun Peng, Jiayi Ren, Yongmei Zhu, Xiangqin Weng, Jiong Hu, Yuanfang Liu, Jie Hao, Weiping Zhang, Duohui Jing, Jian-Qing Mi, JIN WANG

Blood (2025) 146 (Supplement 1): 6880.

https://doi.org/10.1182/blood-2025-6880

Published: 2025

Journal Articles

Phase I study of NPB5005-V283 in patients with relapsed/refractory multiple myeloma

Wanyan Ouyang, William Comrie, Shiwei Jin, Mengmeng Pan, Jie Xu, Yi Tao, Yuanfang Liu, Yan Wang, Weiping Zhang, Xueqiong Song, Cong Wang, Wenshan Hao, Jian-Qing Mi

Blood (2025) 146 (Supplement 1): 2295.

https://doi.org/10.1182/blood-2025-2295

Published: 2025

Journal Articles

A-319, a CD3xCD19 T cell engager, monotherapy for patients with refractory/relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL)

Blood (2025) 146 (Supplement 1): 6853.

https://doi.org/10.1182/blood-2025-6853

Published: 2025

Journal Articles

Efficacy and safety of luspatercept in the treatment of anemia in allo-HSCT for patients with hematological diseases

Shi-wei Jin, Mengmeng Pan, Weiping Zhang, Jiong Hu, Jian-Qing Mi, ling Wang

Blood (2025) 146 (Supplement 1): 2438.

https://doi.org/10.1182/blood-2025-2438

Published: 2025

Journal Articles

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2025-5677

Published: 2025

Journal Articles

Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5666.

https://doi.org/10.1182/blood-2025-5666

Published: 2025

Journal Articles

Real-world study on the impact of continuous treatment dose interruption or reduction of COVALENT BTK inhibitors on efficacy: A 7-year follow-up in chronic lymphocytic leukemia specialized clinics at tertiary hospitals in shanghai, China

Jiaojiao Zhang, Xiaozhong Shen, Jiong Hu, Lu Jiang, JIN WANG, Jian-Qing Mi

Blood (2025) 146 (Supplement 1): 5688.

https://doi.org/10.1182/blood-2025-5688

Published: 2025

Journal Articles

Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed/Refractory Multiple Myeloma

Mengmeng Pan, Di Wang, Jie Xu, Shiwei Jin, Yan Wang, Yi Tao, Yuanfang Liu, Wanyan Ouyang, Xiangqin Weng, Hongmei Yi, Yu Huang, Xinmei Cao, Shuhua Li, Fuyuan Zhang, Weiping Zhang, Chunrui Li, Jian-Qing Mi

Blood blood.2025030559.

https://doi.org/10.1182/blood.2025030559

Published: 2025

Includes: Supplemental data

Journal Articles

Combination of Venetoclax and Daratumumab Plus CAG Regimen in Adult T-Cell Acute Lymphoblastic Leukemia with Persistent Positive Minimal Residual Disease

Lijun Peng, Yuting Dai, Jiayi Ren, Weiyang Liu, Jie Xu, Weiping Zhang, Jin Wang, Jian-Qing Mi

Blood (2024) 144 (Supplement 1): 4210.

https://doi.org/10.1182/blood-2024-204740

Published: 2024

Journal Articles

A Hiplot-Based Web Application for the Rapid Prediction of Adult BCR::ABL1 -Positive and BCR::ABL1 -like B-Cell Precursor Acute Lymphoblastic Leukemia

Jianfeng Li, Yuchen Yan, Cheng Wang, Weiyang Liu, Han Yan, Lingling Zhao, Xiangqin Weng, Yongmei Zhu, Jiayi Ren, Lijun Peng, Jiaojiao Zhang, Yuanfang Liu, Weiping Zhang, Jie Xu, Duohui Jing, Jian-Qing Mi, Jin Wang

Blood (2024) 144 (Supplement 1): 5926.

https://doi.org/10.1182/blood-2024-210369

Published: 2024

Journal Articles

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Gang An, Zhuogang Liu, Jie Jin, Zhen Cai, Wei Li, Zhongjun Xia, Xinan Cen, Yu Hu, Jian-Qing Mi, Hongmei Jing, Rong Zhan, Xiaoyan Qu, Xin Du, Dan Gao, Liang Zhao, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7055.

https://doi.org/10.1182/blood-2024-199908

Published: 2024

Journal Articles

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 498.

https://doi.org/10.1182/blood-2024-193738

Published: 2024

Journal Articles

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Shenmiao Yang, Huayuan Zhu, Ru Feng, Xutao Guo, Ting Niu, Jian-Qing Mi, Zhenling Li, Qianqian Ju, Liru Wang, Yujun Dong, Bingjie Wang, Liang Wang, Wanling Sun, Fang Fang, Liping Su, Yu Zhao, Xiaojun Huang, Jianyong Li

Blood (2024) 144 (Supplement 1): 6773.

https://doi.org/10.1182/blood-2024-206560

Published: 2024

Journal Articles

Flumatinib with Low-Intensity Chemotherapy in Elderly Patients with Newly Diagnosed BCR::ABL1-Positive Acute Lymphoblastic Leukemia

Weiyang Liu, Yuanfang Liu, Yongmei Zhu, Xiangqin Weng, Cheng Wang, Wanyan Ouyang, Jie Xu, Weiping Zhang, Jin Wang, Jian-Qing Mi

Blood (2024) 144 (Supplement 1): 5883.

https://doi.org/10.1182/blood-2024-210222

Published: 2024

Journal Articles

Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1 plus genotyping and MRD Assessment in Adult BCR::ABL1 -Positive Acute Lymphoblastic Leukemia

Cheng Wang, Jianfeng Li, Weiyang Liu, Han Yan, Yuchen Yan, Lingling Zhao, Jiayi Ren, Lijun Peng, Jiaojiao Zhang, Yuanfang Liu, Xiangqin Weng, Yongmei Zhu, Weiping Zhang, Jie Xu, Duohui Jing, Jian-Qing Mi, Jin Wang

Blood (2024) 144 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2024-209664

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Dynamic monitoring of circulating plasma cells in multiple myeloma: A Prospective multicenter study in China

Simvastatin targets the cholesterol–bile acid axis to improve ALL survival by remodeling the metabolic microenvironment

Long-term follow-up for newly diagnosed BCR::ABL1 negative B cell acute lymphoblastic leukemia from China: 10-year outcome of RJ-ALL 2014 protocol

Long-read profiling of structural variants reveals mechanisms of chemo-resistance and prognostic heterogeneity in acute lymphoblastic leukemia

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Association of combined IKZF1plus genotype and ABL1 mutations with outcomes in adult BCR::ABL1-positive acute lymphoblastic leukemia

Phase I study of NPB5005-V283 in patients with relapsed/refractory multiple myeloma

A-319, a CD3xCD19 T cell engager, monotherapy for patients with refractory/relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL)

Efficacy and safety of luspatercept in the treatment of anemia in allo-HSCT for patients with hematological diseases

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)

Real-world study on the impact of continuous treatment dose interruption or reduction of COVALENT BTK inhibitors on efficacy: A 7-year follow-up in chronic lymphocytic leukemia specialized clinics at tertiary hospitals in shanghai, China

Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed/Refractory Multiple Myeloma

Combination of Venetoclax and Daratumumab Plus CAG Regimen in Adult T-Cell Acute Lymphoblastic Leukemia with Persistent Positive Minimal Residual Disease

A Hiplot-Based Web Application for the Rapid Prediction of Adult BCR::ABL1 -Positive and BCR::ABL1 -like B-Cell Precursor Acute Lymphoblastic Leukemia

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Flumatinib with Low-Intensity Chemotherapy in Elderly Patients with Newly Diagnosed BCR::ABL1-Positive Acute Lymphoblastic Leukemia

Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1 plus genotyping and MRD Assessment in Adult BCR::ABL1 -Positive Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only